Grace Therapeutics
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Grace Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Grace Therapeutics: 3 sponsored US clinical trials, none currently recruiting.
Grace Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Aneurysmal Subarachnoid Hemorrhage (aSAH), with 1 trials.
Upper-quartile sponsor footprint
Grace Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
NCT05995405
A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
NCT03361501
A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
NCT03398005
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Therapeutic Areas
How the Grace Therapeutics archive is shaped
3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Aneurysmal Subarachnoid Hemorrhage (aSAH) (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Grace Therapeutics: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Grace Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Grace Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Grace Therapeutics or any single study.
- None of Grace Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Aneurysmal Subarachnoid Hemorrhage (aSAH) is the condition Grace Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Aneurysmal Subarachnoid Hemorrhage (aSAH) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Grace Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.